Oppenheimer Assigns a Buy Rating on Tandem Diabetes Care (TNDM)

Oppenheimer analyst Steven Lichtman assigned a Buy rating to Tandem Diabetes Care (TNDMResearch Report) today and set a price target of $102.00. The company’s shares closed last Tuesday at $94.24.

According to TipRanks.com, Lichtman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.3% and a 49.3% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Zimmer Biomet Holdings, and Merit Medical Systems.

Currently, the analyst consensus on Tandem Diabetes Care is a Moderate Buy with an average price target of $96.67, which is a 9.7% upside from current levels. In a report issued on June 17, Piper Sandler also maintained a Buy rating on the stock with a $90.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $92.95 and a one-year low of $43.69. Currently, Tandem Diabetes Care has an average volume of 1.21M.

Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNDM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.